Medpace Holdings, Inc. Sales Revenue, Services, Net (Deprecated 2018-01-31)
Medpace Holdings, Inc. (MEDP) reported Sales Revenue, Services, Net (Deprecated 2018-01-31) of $0 for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueServicesNet · last filed 2018-05-01
- Medpace Holdings, Inc. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- Medpace Holdings, Inc. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $99.45M, a 4.27% increase year-over-year.
- Medpace Holdings, Inc. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $98.68M, a 4.08% increase year-over-year.
- Medpace Holdings, Inc. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $94.55M, a 2.07% increase year-over-year.
- Medpace Holdings, Inc. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2017 was $386.46M, a 4.27% increase from fiscal 2016.
- Medpace Holdings, Inc. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2016 was $370.62M, a 15.78% increase from fiscal 2015.
- Medpace Holdings, Inc. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2015 was $320.10M.
| Period end | Sales Revenue, Services, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $0.00 10-Q · filed 2018-05-01 | $99.45M derived: sum of 2 quarters · filed 2018-05-01 | $198.13M derived: sum of 3 quarters · filed 2018-05-01 | $292.68M derived: sum of 4 quarters · filed 2018-05-01 |
| 2017-12-31 | $99.45M 10-K · filed 2018-02-27 | $198.13M derived: sum of 2 quarters · filed 2018-02-27 | $292.68M derived: sum of 3 quarters · filed 2018-02-27 | $386.46M 10-K · filed 2018-02-27 |
| 2017-09-30 | $98.68M 10-K · filed 2018-02-27 | $193.23M derived: sum of 2 quarters · filed 2018-02-27 | $287.01M 10-Q · filed 2017-10-31 | $382.39M derived: sum of 4 quarters · filed 2018-05-01 |
| 2017-06-30 | $94.55M 10-K · filed 2018-02-27 | $188.33M 10-Q · filed 2017-08-01 | $283.71M derived: sum of 3 quarters · filed 2018-05-01 | $378.52M derived: sum of 4 quarters · filed 2018-05-01 |
| 2017-03-31 | $93.78M 10-Q · filed 2018-05-01 | $189.16M derived: sum of 2 quarters · filed 2018-05-01 | $283.97M derived: sum of 3 quarters · filed 2018-05-01 | $376.60M derived: sum of 4 quarters · filed 2018-05-01 |
| 2016-12-31 | $95.38M 10-K · filed 2018-02-27 | $190.19M derived: sum of 2 quarters · filed 2018-02-27 | $282.82M derived: sum of 3 quarters · filed 2018-02-27 | $370.62M 10-K · filed 2018-02-27 |
| 2016-09-30 | $94.81M 10-K · filed 2018-02-27 | $187.44M derived: sum of 2 quarters · filed 2018-02-27 | $275.25M 10-Q · filed 2017-10-31 | $360.93M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $92.63M 10-K · filed 2018-02-27 | $180.43M 10-Q · filed 2017-08-01 | $266.11M derived: sum of 3 quarters · filed 2018-02-27 | $347.75M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $87.80M 10-K · filed 2018-02-27 | $173.48M derived: sum of 2 quarters · filed 2018-02-27 | $255.12M derived: sum of 3 quarters · filed 2018-02-27 | $331.87M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $85.68M 10-K · filed 2017-02-28 | $167.32M derived: sum of 2 quarters · filed 2017-02-28 | $244.07M derived: sum of 3 quarters · filed 2017-02-28 | $320.10M 10-K · filed 2018-02-27 |
| 2015-09-30 | $81.64M 10-K · filed 2017-02-28 | $158.39M derived: sum of 2 quarters · filed 2017-02-28 | $234.42M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $76.75M 10-K · filed 2017-02-28 | $152.78M derived: sum of 2 quarters · filed 2017-02-28 | ||
| 2015-03-31 | $76.03M 10-K · filed 2017-02-28 | |||
| 2014-12-31 | $219.79M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |